Searchable abstracts of presentations at key conferences in oncology

oa0001p001 | (1) | PacRim7

S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer

Alexandrou Sarah , Milioli Heloisa Helena , Portman Neil , Lee Christine , Fernandez Kristine , Blake David , Lim Elgene , Caldon C Elizabeth

Endocrine resistant estrogen receptor positive (ER+) breast cancers are dependent upon cyclin-dependent kinases (CDK) 4/6 for proliferation, making them highly suitable for CDK4/6 inhibitor treatment. Despite initial efficacy, acquired resistance to CDK4/6 inhibitors is emerging and is now a major consideration in pre-clinical and clinical drug development. Current models of CDK4/6 inhibitor resistance do not mimic the clinical scenario where CDK4/6 inhibition will occur in th...

oa0001p034 | (1) | PacRim7

Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer

Milioli Heloisa Helena , Chia Kee Ming , Portman Neil , Yong Aliza , Tarulli Gerald , Selth Luke , Tilley Wayne , Hickey Theresa , Lim Elgene

Steroid hormone receptors (SHR) play a major role in the normal breast development and breast cancer progression. Estrogen receptor (ER) is expressed in approximately 75% of breast cancers, and the majority of these tumours also express the androgen receptor (AR). While ER-directed therapies have been effective in the majority of patients, a significant subset develops resistance and requires alternative treatment approaches. In the endocrine-resistant setting, emerging insigh...

oa0001p049 | (1) | PacRim7

DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer

Stirzaker Clare , Chia Kee Ming , Portman Neil , Milioli Heloisa Helena , Clifton Samuel , Achinger-Kawecka Joanna , Nair Shalima , Lim Elgene , Clark Susan J

Seventy percent of breast cancers are classified as estrogen-receptor positive (ER+) and ER is the key proliferative driver in these tumours. Clinically, ER+ patients receive ER-targeted (endocrine) therapies to inhibit ER activity and whilst these agents reduce the risk of recurrence, up to 43% patients develop drug resistance within 15 years. Hence, identification of mechanisms underlying these resistant mechanisms could extend the use of endocrine-therapies. Profound altera...